Abstract
We report the preliminary results of a prospective study demonstrating tetrofosmin uptake in surgically and histologically proven parathyroid adenomas. In ten patients with primary chronic hyperparathyroidism, parathyroid imaging was performed using (1) technetium-99m methoxyisobutylisonitrile (MIBI) and (2)99mTc-1,2-bis(bis(2-ethoxyethyl)phosphino)ethane (tetrofosmin) within a time interval of 3–5 days. Both tracers correctly identified the parathyroid adenomas by focal prolonged tracer retention. On visual inspection image contrast was generally higher with MIBI than with tetrofosmin in all the patients studied. Tetrofosmin showed a slower elimination from the parathyroid adenomas than MIBI in six of the ten cases. Our preliminary results show that tetrofosmin, like MIBI, as a feasible, sensitive tracer for parathyroid scintigraphy. For routine use, the rapid kit preparation without heating and the lower radiation dose to the patient make tetrofosmin an alternative tracer for parathyroid scintigraphy. Further evaluation is needed to determine which of the two tracers is the more sensitive for the detection of parathyroid adenomas, and which tracer properties better reflect the degree of endocrine activity.[/p]
References
Casaraca D, Rubello D, Saladini G, etal. Clinical role of Tc99m-MIBI scintigraphy in parathyroid imaging, a comparative study with T1-201 scintigraphy, echography and CT.Eur J Nucl Med 1991; 18: 531.
Kelley JD, Forster AM, Higley B, etal. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging.J Nucl Med 1993; 34: 222–227.
Civelek AC, Durski K, Shafique I, etal. Failure of perchlorate to inhibit Tc-99m-isonitrile binding by the thyroid during myocardial perfusion studies.Clin Nucl Med 1991; 16: 358–361.
Piwicna-Worms D, Chin ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.Cancer Res 1993; 53: 977–984.
Sandrock D, Merino MJ, Norton JA, Neumann RD. Ultrastructural histology correlates with results of thallium201/technetium-99m parathyroid substration scintigraphy.J Nucl Med 1993; 34: 24–29.
Wackers FJ, Berman DJ, Maddahi J, Watson DD, Beller GA, Strauss HW Boucher CA, Picard M, Holman BL, Fridrich R, Inglese E, Delaloye B, Bischof-Delaloye A, Camin L, McKusik K. Technetium-99m-hexakis-2-methoxyisobutylisonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging.JNucl Med 1989; 30: 301–311.
Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study).J Nucl Med 1992; 33: 1801–1807.
O'Doherty JO, Kettle AG, Wells P, etal. Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies.J Nucl Med 1992; 33: 313.
Osmanagaoglu K, Schelstraete K, Lippens M, Obrie E, De Feyter I. Visualization of a parathyroid adenoma with Tc-99m MIBI in a case with iodine saturation and impaired tallium uptake.Clin Nucl Med 1993; 18: 214–216.
Higley B, Smith FW Smith T, Gemmell HG, etal. Technetium-99m-1,2bis(bis(2-ethoxy-ethyl)phosphino)ethane: human biodistribution, dosimetry, and safety of a new myocardial perfusion imaging agent.J Nucl Med 1993; 34: 30–38.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aigner, R.M., Fueger, G.F. & Nicoletti, R. Parathyroid scintigraphy: comparison of technetium-99m methoxyisobutylisonitrile and technetium-99m tetrofosmin studies. Eur J Nucl Med 23, 693–696 (1996). https://doi.org/10.1007/BF00834533
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00834533